VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods
VivoSim Labs (VIVS) welcomed an FDA regulatory update clarifying the use of non-animal methods to test drug and biological product safety.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
VivoSim Labs (VIVS) welcomed an FDA regulatory update clarifying the use of non-animal methods to test drug and biological product safety.
The direct final rule replaces “animal tests” with “nonclinical tests” across the FDA’s regulatory framework. It clarifies that non-animal methods can be used where appropriate for products intended for human use, opening pathways for human cell-based tests such as VivoSim’s.
VivoSim said its long-duration models, based on primary human cells, can identify and distinguish liver injury and gastrointestinal toxicity risks earlier in development and have ranked clinical safety risks for clients’ drug candidates. Its stated aim is to help clients rule out likely failures before selecting a drug for clinical testing, avoiding spending on candidates that later fail.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointFDA regulatory update opens pathways for non-animal safety testing, including human cell-based methods such as VivoSim’s.
Negative
- None.
Details
Market Reaction – VIVS
On Oct 7, the day this news came out, the latest delayed price for VIVS is 0.10% above the previous close. Argus tracked a peak move of +3.4% during the session. Our momentum scanner has recorded 7 alerts for this stock so far that day. The latest delayed price is $0.20. Relative volume is exceptionally heavy at 6.8x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Drug-development spending cited
- $50 to $200M
- Per drug, potentially avoided by identifying risky candidates earlier
- Cost per approved drug cited
- Up to $2B
- Article says this reflects the cost of failed drugs as well
- Failed drugs per approved drug
- 11 failed drugs
- Article’s explanation of the cited cost per approved drug
- Clinical-trial success rate scenario
- 8% to 30%
- Conditional scenario cited by the executive chairman
- Drug-development cost reduction scenario
- 50%
- Conditional on increasing the clinical-trial success rate to 30%
Historical Context
-
Presented liver and intestinal toxicity findings that ranked safety risks and differentiated ADC toxicities.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
new approach methodologies technical
direct final rule regulatory
drug-induced liver injury medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
As the FDA opens the door to non-animal safety testing, VivoSim's human-relevant models are already helping lower drug costs
SAN DIEGO, Oct. 07, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today celebrated the U.S. Food and Drug Administration's (FDA) direct final rule updating its regulations to clarify that non-animal methods can be used where appropriate for testing the safety of drugs and biological products intended for human use.
The FDA’s new rule replaces the term "animal tests" with "nonclinical tests" across its regulatory framework, formally opening pathways for NAMs, including human cell-based tests such as those offered by VivoSim.
VivoSim's liver tissue models are capable of flagging drug candidates likely to cause liver toxicity, side effects like diarrhea, and other issues. Liver toxicity is the leading cause of drug failures and market withdrawals. The company has the ability to meaningfully de-risk a client company’s set of compounds and rule out likely failures prior to its selection of a drug to enter clinical testing.
Drug-induced liver injury (DILI) and gastrointestinal (GI) toxicity remain leading causes of drug candidate attrition. VivoSim's findings demonstrate how its long-duration, primary human cell-based models can help identify and differentiate these risks earlier in development, successfully ranking clinical safety risks for clients’ drug candidates.
“VivoSim’s NAMkind Models give insights that let our pharma and biotech partners make fewer major mistakes,” said Keith Murphy, VivoSim’s Executive Chairman. “By identifying risky molecules early on in development and moving on to better candidates, they avoid spending
By offering these kinds of insights, VivoSim also is helping with society’s goal of lowering the cost of medicines for patients. The cited costs of up to
About VivoSim Labs
VivoSim Labs, Inc. (“VivoSim” and the “Company”), is a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional (“3D”) human tissue models of liver and intestine. The Company offers partners liver and intestinal toxicology insights using its new approach methodologies (“NAM”) models. The Company anticipates accelerated adoption of human tissue models following the U.S. Food and Drug Administration (“FDA”) Roadmap to refine animal testing requirements in favor of these non-animal NAM methods. VivoSim Labs operates from San Diego, CA. Visit www.vivosim.ai.
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Forward-looking statements include statements regarding the Company’s cash on hand, revenue growth guidance and the Company’s progress in marketing contract research services using NAMs models to pharmaceutical companies. Such forward-looking statements are not guarantees of performance and actual actions or events could differ materially from those contained in such statements. These risks and uncertainties and other factors are identified and described in more detail in the Company’s filings with the SEC, including its Annual Report on Form 10-K filed with the SEC on July 14, 2026, as such risk factors are updated in its most recently filed Quarterly Report on Form 10-Q filed with the SEC on August 12, 2026. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that the Company may issue in the future. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events, or circumstances or to reflect the occurrence of unanticipated events.
Contact(s):
Investor Relations
info@vivosim.ai
VivoSim Labs, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the FDA’s non-animal testing rule mean for VivoSim Labs?
The FDA’s direct final rule clarifies that non-animal methods can be used where appropriate for safety testing of drugs and biological products intended for human use. Replacing “animal tests” with “nonclinical tests” opens regulatory pathways for human cell-based methods, including those offered by VivoSim.